Seroepidemiological Assessment of the Spread of SARS-CoV-2 Among 25 and 28 Year-old Adult Women in Finland Between March 2020-June 2022

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Jul 11

PMID 38990856

Authors

Penelope Gray

Tiina Eriksson

Lovisa Skoglund

Camilla Lagheden

Ceke Hellstrom

Elisa Pin

Anna Suomenrinne-Nordvik

Ville N Pimenoff

Peter Nilsson

Joakim Dillner

Matti Lehtinen

Affiliations

Soon will be listed here.

Abstract

Introduction: Serological surveys of the prevalence of SARS-CoV-2 are instrumental to understanding the course of the COVID-19 epidemic. We evaluate the seroprevalence of SARS-CoV-2 among young adult Finnish females residing in 25 communities all over Finland from 2020 until 2022.

Methods: Between 1st March 2020 and 30th June 2022, 3589 blood samples were collected from 3583 women born in 1992-95 when aged 25 or 28 years old attending the follow-up of an ongoing population-based trial of cervical screening strategies. The crude and population standardized SARS-CoV-2 seroprevalence was measured using nucleocapsid (induced by infection) and spike wild-type (WT) protein (induced both by infection and by vaccination) antigens over time and stratified by place of residence (inside or outside the Helsinki metropolitan region).

Results: During 2020 (before vaccinations), spike-WT and nucleocapsid IgG antibodies followed each other closely, at very low levels (<5%). Spike-WT seropositivity increased rapidly concomitant with mass vaccinations in 2021 and reached 96.3% in the 2nd quartile of 2022. Antibodies to nucleocapsid IgG remained relatively infrequent throughput 2020-2021, increasing rapidly in the 1st and 2nd quartiles of 2022 (to 19.7% and 56.6% respectively). The nucleocapsid IgG seropositivity increased more profoundly in participants residing in the Helsinki metropolitan region (4.5%, 8.4% and 43.9% in 2020, 2021 and 2022 respectively) compared to those residing in communities outside the capital region (4.5%, 4.3% and 34.7%).

Conclusions: Low SARS-CoV-2 infection-related seroprevalence during 2020-2021 suggest a comparatively successful infection control. Antibodies to the SARS-CoV-2 WT spike protein became extremely common among young women by the end of 2021, in line with the high uptake of SARS-CoV-2 vaccination. Finally, the rapid increase of seroprevalences to the SARS-CoV-2 nucleocapsid protein during the first and second quartile of 2022, imply a high incidence of infections with SARS-CoV-2 variants able to escape vaccine-induced protection.

References

Hassan S, Seigerud A, Abdirahman R, Arroyo Muhr L, Nordqvist Kleppe S, Pin E . SARS-CoV-2 infections amongst personnel providing home care services for older persons in Stockholm, Sweden. J Intern Med. 2021; 290(2):430-436. PMC: 8250663. DOI: 10.1111/joim.13274. View

Link-Gelles R, Levy M, Natarajan K, Reese S, Naleway A, Grannis S . Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open. 2023; 6(3):e232598. PMC: 10018321. DOI: 10.1001/jamanetworkopen.2023.2598. View

Tegnell A, Besso A, Bjorkholm B, Byfors S, Carlson J, Tegmark Wisell K . Implementation of a broad public health approach to COVID-19 in Sweden, January 2020 to May 2022. Euro Surveill. 2023; 28(41). PMC: 10571492. DOI: 10.2807/1560-7917.ES.2023.28.41.2300063. View

Hober S, Hellstrom C, Olofsson J, Andersson E, Bergstrom S, Falk A . Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay. Clin Transl Immunology. 2021; 10(7):e1312. PMC: 8288725. DOI: 10.1002/cti2.1312. View

Solastie A, Nieminen T, Ekstrom N, Nohynek H, Lehtonen L, Palmu A . Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020-2022. Emerg Microbes Infect. 2023; 12(2):2222849. PMC: 10291939. DOI: 10.1080/22221751.2023.2222849. View

Dillner J, Elfstrom K, Blomqvist J, Eklund C, Lagheden C, Nordqvist-Kleppe S . Antibodies to SARS-CoV-2 and risk of past or future sick leave. Sci Rep. 2021; 11(1):5160. PMC: 7933367. DOI: 10.1038/s41598-021-84356-w. View

Barchuk A, Skougarevskiy D, Titaev K, Shirokov D, Raskina Y, Novkunkskaya A . Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study. Sci Rep. 2021; 11(1):12930. PMC: 8217236. DOI: 10.1038/s41598-021-92206-y. View

Ahava M, Jarva H, Jaaskelainen A, Lappalainen M, Vapalahti O, Kurkela S . Rapid increase in SARS-CoV-2 seroprevalence during the emergence of Omicron variant, Finland. Eur J Clin Microbiol Infect Dis. 2022; 41(6):997-999. PMC: 9049924. DOI: 10.1007/s10096-022-04448-x. View

Bastola K, Nohynek H, Lilja E, E Castaneda A, Austero S, Kuusio H . Incidence of SARS-CoV-2 Infection and Factors Associated With Complete COVID-19 Vaccine Uptake Among Migrant Origin Persons in Finland. Int J Public Health. 2023; 68:1605547. PMC: 10189547. DOI: 10.3389/ijph.2023.1605547. View

10.

Tiirinki H, Viita-Aho M, Tynkkynen L, Sovala M, Jormanainen V, Keskimaki I . COVID-19 in Finland: Vaccination strategy as part of the wider governing of the pandemic. Health Policy Technol. 2022; 11(2):100631. PMC: 9008981. DOI: 10.1016/j.hlpt.2022.100631. View

11.

Pimenoff V, Elfstrom M, Baussano I, Bjornstedt M, Dillner J . Estimating Total Excess Mortality During a Coronavirus Disease 2019 Outbreak in Stockholm, Sweden. Clin Infect Dis. 2020; 72(11):e890-e892. PMC: 7665438. DOI: 10.1093/cid/ciaa1593. View

12.

Tahtinen P, Ivaska L, Jalkanen P, Kakkola L, Kainulainen L, Hytonen J . Low pre-vaccination SARS-CoV-2 seroprevalence in Finnish health care workers: a prospective cohort study. Infect Dis (Lond). 2022; 54(6):448-454. DOI: 10.1080/23744235.2022.2027008. View

13.

Ogata T, Tanaka H, Irie F, Nozawa Y, Noguchi E, Seo K . A low proportion of asymptomatic COVID-19 patients with the Delta variant infection by viral transmission through household contact at the time of confirmation in Ibaraki, Japan. Glob Health Med. 2022; 4(3):192-196. PMC: 9243404. DOI: 10.35772/ghm.2021.01116. View

14.

Louvanto K, Eriksson T, Gray P, Apter D, Baussano I, Bly A . Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women. Int J Cancer. 2019; 147(2):440-447. DOI: 10.1002/ijc.32802. View

15.

Day M . Covid-19: Italy confirms 11 deaths as cases spread from north. BMJ. 2020; 368:m757. DOI: 10.1136/bmj.m757. View

16.

Baum U, Poukka E, Palmu A, Salo H, Lehtonen T, Leino T . Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill-An interim analysis of a nationwide cohort study. PLoS One. 2021; 16(11):e0258704. PMC: 8601574. DOI: 10.1371/journal.pone.0258704. View

17.

Kant R, Truong Nguyen P, Blomqvist S, Erdin M, Alburkat H, Suvanto M . Incidence Trends for SARS-CoV-2 Alpha and Beta Variants, Finland, Spring 2021. Emerg Infect Dis. 2021; 27(12):3137-3141. PMC: 8632157. DOI: 10.3201/eid2712.211631. View

18.

Salo H, Lehtonen T, Auranen K, Baum U, Leino T . Predictors of hospitalisation and death due to SARS-CoV-2 infection in Finland: A population-based register study with implications to vaccinations. Vaccine. 2022; 40(24):3345-3355. PMC: 9023344. DOI: 10.1016/j.vaccine.2022.04.055. View

19.

Hellewell J, Abbott S, Gimma A, Bosse N, Jarvis C, Russell T . Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet Glob Health. 2020; 8(4):e488-e496. PMC: 7097845. DOI: 10.1016/S2214-109X(20)30074-7. View

20.

Erikstrup C, Laksafoss A, Gladov J, Kaspersen K, Mikkelsen S, Hindhede L . Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study. Lancet Reg Health Eur. 2022; 21:100479. PMC: 9355516. DOI: 10.1016/j.lanepe.2022.100479. View